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New complexes of samarium(III), gadolinium(III), and dysprosium(III) with coumarin-3-carboxylic acid (HCCA) were prepared
by the reaction of the ligand with respective metal nitrates in ethanol. The structures of the ﬁnal complexes were determined by
means of physicochemical data, elemental analysis, IR and Raman spectra. The metal-ligand binding mode in the new Ln(III)
complexes of coumarin-3-carboxylic acid was elucidated. The vibrational study gave evidence for bidentate coordination of CCA
−
to Ln(III) ions through the carbonylic oxygen and the carboxylic oxygen atoms. The complexes were tested for antiproliferative
activitiyonthechronicmyeloidleukemia-derivedK-562,overexpressingtheBCR-ABLfusionprotein.Cytotoxicitytowardstumor
cells was determined for a broad concentration range. The samarium salt exerted a very weak antiproliferative eﬀect on these cells.
This is in contrast to the lanthanide complexes, especially samarium complex, which exhibited potent antiproliferative activity.
Thepresentstudyconﬁrmsourpreviousobservationsthatthelanthanidecomplexesofcoumarinsexhibitantiproliferativeactivity
towards K-562 cell line.
Copyright © 2007 Irena Kostova et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Coumarin (1,2-benzopyrone) is structurally the least com-
plex member of a large class of compounds known as benzo-
pyrones [1].Thebiologicalactivitiesofcoumarinandrelated
compounds are multiple and include antithrombotic activity
[2] and antimicrobial properties [3]. In addition, coumarins
have been shown to inhibit N-methyl-N-nitrosourea, af-
latoxin B1 and 7,12-dimethylbenz(a)anthracene-induced
mammarycarcinogenesisinrats[4,5]. More recently, coum-
arin derivatives have been evaluated in the treatment of hu-
man immunodeﬁciency virus, due to their ability to in-
hibit human immunodeﬁciency virus integrase [6, 7]. Since
the late 1980s, a number of in vitro and in vivo studies
have investigated the possible use of coumarins in the treat-
ment of cancer [8]. The in vitro eﬀects of coumarins on
the growth of renal cell carcinoma that derived cell lines
showed that coumarin and 7-hydroxycoumarin were potent
cytotoxic and cytostatic agents [9]. Several authors have re-
ported on the use of coumarin (1,2-benzopyrone), or its
metabolite 7-hydroxycoumarin, for the treatment of some
human carcinomas [10–13]. There are several reports indi-
cating that some coumarin compounds, including coumarin
and 7-hydroxycoumarin, inhibit cell growth of cell lines of
various types of cancer [14–18].
The coumarin derivatives have been the focus of our re-
cent research concerning the design of new cytotoxic agents.
It is well known that many investigations have proved that
binding of a drug to a metalloelement enhances its activity
and, in some cases, the complex possesses even more heal-
ing properties than the parent drug. This has prompted us to
investigate the metal binding properties of several coumarin
derivatives. We have recently reported the synthesis of lan-
thanide(III) complexes with some coumarins and the study
of their anticancer activity [19–29]. In previous works [19–
29], we investigated the coordination behavior of some 4-
hydroxycoumarins with cerium(III), lanthanum(III), and
neodymium(III). In the course of these studies, considering2 Metal-Based Drugs
OO
O
C
OH
1
2
3
4 5
6
7
82  
3 
Figure 1: The structure of the ligand (HCCA, coumarin-3-carbox-
ylic acid).
that lanthanides(III) have an interesting but not well-known
biological role in living organisms as trace elements, we have
investigated the coordination properties of a series of other
lanthanides(III) with coumarin derivatives.
Thus, the aim of this work is to synthesize and character-
ize complexes of samarium(III), gadolinium(III), and dys-
prosium(III) with coumarin-3-carboxylic acid (see Figure 1)
and to determine the antiproliferative eﬀects of these com-
plexes against the chronic myeloid leukemia-derived K-562.
The cell line is characterized with a strong expression of
BCR-ABL fusion protein (a constitutive nonreceptor tyro-
sine kinase) which determines the low responsiveness of
these cells to proapoptotic stimuli [30].
2. METHODS
2.1. Chemistry
ThecompoundsusedforpreparingthesolutionswereMerck
products, p.a. grade: Sm(NO3)3 ·6H2O, Gd(NO3)3 ·6H2O,
and Dy(NO3)3 ·5H2O. Coumarin-3-carboxylic acid (Figure
1) was used for the preparation of metal complexes as a lig-
and.
The complexes were synthesized by reaction of samar-
ium(III), gadolinium(III), and dysprosium(III) salts and the
ligand, in amounts equal to metal: ligand molar ratio of 1 : 2.
The synthesis of the complexes was made in diﬀerent ratios
(1 : 1, 1 : 2, 1 : 3)butinallthecasestheproductwaswiththe
composition 1 : 2. The complexes were prepared by adding
ethanol solutions of Ln(III) salts to ethanol solutions of the
ligand. The reaction mixture was stirred with an electromag-
netic stirrer at 25◦C for one hour. At the moment of mixing
of the solutions, precipitates were obtained. The precipitates
were ﬁltered, washed several times with water and ethanol,
and dried in a desiccator to constant weight.
The complexes were insoluble in water, methanol, and
ethanol and well soluble in DMSO.
Thecarbon,hydrogen,andnitrogencontentsofthecom-
pounds were determined by elemental analysis. The water
content was determined by Metrohn Herizall E55 Karl Fisher
Titrator and was conﬁrmed by TGA.
IR spectra (Nujol) were recorded on IR-spectrometer
FTIR-8101M Shimadzu. The Raman spectra of the ligand
and their new Ln(III) complexes were recorded with a Dilor
microspectrometer (Horiba-Jobin-Yvon, model LabRam)
equipped with a 1800grooves/mm holographic grating. The
514.5nm line of an argon ion laser (Spectra Physics, model
2016) was used for the probes excitation. The spectra were
collected in a backscattering geometry with a confocal Ra-
man microscope equipped with an Olympus LMPlanFL 50x
objective and with a resolution of 2cm−1. The detection of
Raman signal was carried out with a Peltier-cooled CCD
camera. The laser power of 100mW was used in our mea-
surements.
2.2. Pharmacology
The antiproliferative eﬀects of the tested lanthanide com-
plexesandofthecorrespondingnitratesaltswereassessedon
the chronic myeloid leukemia-derived K-562. The cells were
maintained as suspension-type cultures in a controlled envi-
ronment: RPMI 1640 medium (Sigma), with 10% heat inac-
tivated fetal bovine serum (Sigma) and 2mM L-glutamine
(Sigma), in a “Heraeus” incubator with humidiﬁed atmo-
sphere and 5% carbon dioxide, at 37◦C. In order to keep the
cells in log phase, cell suspension was discarded 2 or 3 times
perweekandthecellculturewasrefedwithfreshRPMI-1640
aliquots.
The cell viability was determined using the MTT-dye
reduction assay. Brieﬂy, exponentially growing cells were
seeded in 96-well microplates (100μl/well) at a density of
1 × 105 cells per ml and after 24-hour incubation at 37◦C
they were exposed to various concentrations of the lan-
thanide complexes for 48 hours. For each concentration a
set of 6 wells was treated. After the incubation with the test
compounds MTT solution (10mg/ml in PBS) was added
(10μl/well). The plates were further incubated for 4 hours
at 37◦C and the formazan crystals formed were dissolved
through addition of 100μl/well 5% solution of formic acid
in 2-propanol (Merck). The absorption of the samples was
then measured using an ELISA reader (Uniscan Titertec) at
wavelength of 580nm. The blank solution consisted of 100μl
RPMI 1640 medium (Sigma), 10μl MTT stock, and 100μl
5% formic acid in 2-propanol. The survival fractions were
calculated as percentage of the untreated control using the
formula
SF % =
Atest
Acontrol
×100, (1)
where Atest is the average value for the absorption at a given
concentration and Acontrol is the average absorption of the
untreated control, respectively.
The stock solutions of the tested lanthanide complexes
(at 20mM) were freshly prepared in DMSO, and thereafter
consequently diluted in RPMI-1640 medium, in order to
achievethedesiredﬁnalconcentrations.Attheﬁnaldilutions
obtained, the concentration of DMSO never exceeded 1%.
The stock solutions (20mM, in water) of the nitrate salts of
the lanthanides were freshly prepared and following antibac-
terial ﬁltration they were accordingly diluted in RPMI-1640
medium.
Dataprocessing,generationofdose-responsecurves,and
IC50 calculations were performed using Microsoft Excel and
Microcal Origin software for PC.Irena Kostova et al. 3
Table 1: Elemental analysis of Ln(III) complexes of coumarin-3-
carboxilic acid. HCCA = C10H6O4; CCA = C10H5O4
−.
Compound Calculated/found (%)
Formulae CH N H 2OL n
Sm(CCA)2(NO3) ·H2O 39,47/ 1,97/ 2,30/ 2,96/ 24,67/
39,09 2,02 2,77 2,73 24,25
Gd(CCA)2(NO3) ·H2O 39,02/ 1,95/ 2,28/ 2,92/ 25,53/
39,38 2,28 2,49 2,69 25,22
Dy(CCA)2(NO3) ·H2O 38,71/ 1,94/ 2,26/ 2,90/ 26,13/
38,90 1,86 2,05 2,58 25,84
3. RESULTS AND DISCUSSION
3.1. Chemistry
The new complexes were characterized by elemental anal-
ysis. The metal ions were determined after mineralization.
The water content in the complexes was determined by Karl
Fisher analysis. The nature of the complexes was conﬁrmed
by IR and Raman spectroscopy.
The data of the elemental analysis of the compounds ob-
tained serving as a basis for the determination of their em-
pirical formulas and the results of the Karl Fisher analysis are
presented in Table 1. There is good agreement between the
calculated and the found values.
The mode of bonding of the ligand to samarium(III),
gadolinium(III), and dysprosium(III) ions was elucidated
by recording the IR and Raman spectra of the complexes
as compared with those of the free ligand. The vibrational
spectra of the complexes showed new bands in comparison
with these of the free ligand which have been assigned to
the rocking, waggling, and metal-oxygen stretching vibra-
tions.
3.2. Vibrationalanalysis
Dependingontheorientationofthetwodonorgroups,C=O
and COO−,d i ﬀerent binding of the anion of coumarin-3-
carboxylic acid (CCA−) is possible. However, in most of the
known lanathanide complexes, the metal-ligand interaction
is mainly electrostatic by nature. To help further the binding
mode elucidation in the new Sm(III), Gd(III), and Dy(III)
complexes of HCCA, detailed vibrational analysis was per-
formed on the basis of comparison of experimental vibra-
tional spectra of HCCA and its Sm(III), Gd(III), and Dy(III)
complexes with those theoretically predicted by us earlier
[31]a sw e l la sw i t hl i t e r a t u r ed a t aa b o u tr e l a t e dc o m p o u n d s .
The data of the experimental FT-IR and FT-Raman spectra
of HCCA and its Sm(III), Gd(III), and Dy(III) complexes are
given in Table 2. The FT-Raman spectra of the ligand and its
Ln(III) complexes are presented in Figure 2.
The broadband at 3176cm−1 in the IR spectrum of the
ligand was assigned to the ν(OH) vibrational mode. This
band was not detected in the spectra of the complexes, indi-
cating that the deprotonated ligand form participates in the
complexes. The bands in the 3060–2920cm−1 region were
assigned to ν(CH) modes of HCCA. In the IR spectra of
Sm(III), Gd(III), and Dy(III)complexestheyremainalmost
unchanged.
The strong IR bands at 1746cm−1 and 1685cm−1
and the medium Raman bands at 1729, 1676, and
1663cm−1 were assigned to ν(C=O) modes of the car-
boxylic and carbonylic groups, respectively. The high IR in-
tensity of these bands retained in the spectra of Sm(III),
Gd(III), and Dy(III) complexes, the ν(C=O)carboxylic band
was shifted to lower frequency (1703cm−1, 1703cm−1,
1705cm−1 for Sm(III), Gd(III), and Dy(III) complexes,
resp.), and the ν(C=O)carbonylic band showed also a
position change (1672cm−1, 1672cm−1, 1674cm−1 for
Sm(III), Gd(III), and Dy(III) complexes, resp.). The same
shift eﬀects were observed in the Raman spectra of the com-
plexes.
In agreement with the literature data [31], the bands
observed in the 1650–1330cm−1 frequency range are due
to the ν(CC) stretching vibrations of HCCA coumarin
ring. The bands that are typical for the coumarin vi-
brations were not shifted signiﬁcantly in the spectra of
Sm(III), Gd(III), and Dy(III) complexes, which indicated
that the Ln(III) cations did not produce substantial polar-
ization on the coumarin ring. The strong IR (at 1613 and
1569cm−1) and Raman (at 1608 and 1559cm−1) bands are
attributed to the ν(C=C) stretching vibrations of HCCA
coumarin fragment. Their positions and intensities are al-
most retained and the second band is split in the complexes.
The bands at 1489, 1453, and 1374cm−1 (IR) and at 1483,
1442, and 1363cm−1 (Raman), which also are assigned to
the ν(CC) modes of HCCA, show shifts in the IR and Ra-
man spectra of Sm(III), Gd(III), and Dy(III) complexes and
at the same time the intensity of these bands increases. The
induced polarization by Ln(III)−CCA interaction produces
electron density distribution in the conjugated coumarin
ring and as a result the ν(CC) frequencies change their po-
sitions and intensity.
The strong bands at 1228cm−1 (IR spectrum of HCCA)
and at 1216cm−1 (Raman spectrum of HCCA) and the
medium one at 989cm−1, in the IR spectrum of HCCA,
were assigned to the lactone ν(C−O) modes, respectively. In
the complexes, these modes were shifted to lower frequency.
In agreement with Ln(III)−Ocarbonyl interaction, the induced
polarization on CCA− leads to changes of the C−Ol a c t o n e
bond lengths as well as of their frequencies in a direction
mentioned above.
The following bands, observed in the IR spectra of the
complexes, are assigned to the vibrational modes of the
NO3 group: 1263cm−1 (Sm complex), 1262cm−1 (Gd com-
plex), 1262cm−1 (Dy complex) for ν(NO)bonded; 1053cm−1
(Sm complex), 1049cm−1 (Gd complex), 1049cm−1 (Dy
complex) for δ(ONO); 786cm−1 (Sm complex), 791cm−1
(Gd complex), 781cm−1 (Dy complex) for δ(ONO); and
725cm−1 (Sm complex), 725cm−1 (Gd complex), 713cm−1
(Dy complex) for δ(ONO). Some of them also appear in
the Raman spectra of the complexes: 1040cm−1 (Sm com-
plex), 1040cm−1 (Gd complex), 1043cm−1 (Dy complex)
for δ(ONO); 777cm−1 (Sm complex), 772cm−1 (Gd com-
plex), 777cm−1 (Dy complex) for δ(ONO). Because of the4 Metal-Based Drugs
Table 2: Experimental vibrational frequencies of HCCA and its Ln(III) complexes.
HCCA Sm-HCCA Gd-HCCA Dy-HCCA Assignments
IR Raman IR Raman IR Raman IR Raman
3176w — —————— ν(OH)coum
3057w 3066w 3050w — 3051w — 3054w — ν(CH)
2956w — 2953vw — 2953vw — 2953w — ν(CH)
2926w — 2924w — 2922w — 2924w — ν(CH)
1746vs 1729m 1703m 1692m 1703s 1692m 1705vs 1690m ν(C=O)carboxylic
1685s 1676m 1672vs 1660m 1672s 1659m 1684sh 1659m ν(C=O)carbonylic
— 1663m ———— 1674s — —
1613s 1608vs 1613vs 1600vs 1613vs 1600vs 1615vs 1600vs ν(CC)
1569s 1559m 1572s 1561s 1572s 1561s 1581vs 1563s ν(CC)
—— 1553s 1540m 1556s 1540m 1556s 1538m —
1489w 1483w 1510m 1445m 1512m 1448m 1485vw 1447m ν(CC)+δ(CCH)ip
1453w 1442w 1456m 1406w 1458m 1406m 1458m 1405w ν(CC)+δ(CCH)ip
—— 1408s — 1410s 1380br 1408s — —
1422s 1413vw —————— δ(COH)ip
1374m 1363s 1355w 1323m 1356w 1323m 1385vs 1320m ν(CC)+δ(CCH)ip
1228s 1216s — 1204s — 1207s 1215w 1204s ν(C−O)lactone
1208s 1197vs 1299sh 1275w 1287sh 1278w 1255m 1278w ν(C−O)carboxylic
—— 1282s — 1283m — —— —
—— 1263m — 1262m — 1262m — ν(NO)as
—— 1053w 1040m 1049w 1040m 1049w 1043m δ(ONO)
989m — 976w 984w 971vw — 964w 986w δ(CCH)op
802s — —————— δ(COH)op
——786w 777w 791vw 772w 781w 777w δ(ONO)
——767m — 768m — 766s — δ(OCO)ip(cabox)
+ν(Ln−O)carboxylic ——748w 740m 749w 740m 750w 740m
——725vw — 725vw — 713vw — δ(ONO)
——459w 468w 457w 475w 457w 469w ν(Ln−O)carbonylic
——449w — 449w — 449w — —
—— No data 209w No data 206w No data 211vw ν(Ln−ONO3)
predominant electrostatic character of the Ln−O bonding,
the bands corresponding to the ν(Ln−O) modes have low
intensities, they are coupled with other modes and hence,
their assignment is unreliable. The doublet bands observed
in the IR spectra of the complexes at 767, 748cm−1 (Sm
complex), 768, 749cm−1 (Gd complex), 766, 750cm−1 (Dy
complex), the bands at 459cm−1 (Sm complex), 457cm−1
(Gd complex), 457cm−1 (Dy complex), and the bands at
449cm−1 for Sm(III), Gd(III), and Dy(III) complexes were
assigned to ν(Ln−O)carboxylic and ν(Ln−O)carbonylic modes,
respectively.
On the basis of the above-detailed vibrational study we
can conclude that the metal-ligand bonding in Ln(III) com-
plexesofcoumarin-3-carboxylicacidappearedtobestrongly
ionic with very small donor-acceptor character. The vibra-
tional study gave evidence for bidentate coordination of
CCA− toSm(III), Gd(III), and Dy(III)ionsthroughthecar-
bonylic oxygen and the carboxylic oxygen.
A survey of the 1H NMR spectral data reveals downﬁeld
chemical shifts of the protons in the Ln(III) complexes spec-
tra relative to the free ligand. The resonances due to protons
of the ligand are considerably broadened and shifted indi-
cating complexation. The ligand shows a peak at 13.2ppm
due to the carboxylic proton [31]. This peak is absent in the
spectra of the complexes due to the deprotonation of the car-
boxylic group. In the 13C NMR spectra of the complexes,
the largest upﬁeld chemical shifts are observed for the car-
bon atoms which are neighbors of the carboxylic and car-
bonylic oxygens and this ﬁnding conﬁrms their participation
in Ln(III)−CCA interaction.
ThesolventDMSOwasusedfortheNMR measurements
because the solubility of the complexes in noncoordinating
solvents was too low. DMSO is well known as a very reac-
tive agent. DMSO molecule could indeed bind to the metal
and give rise to equilibrium, fast on the NMR time scale,
involving the DMSO molecule as an additional ligand, be-
cause of the high coordination number of Ln(III). Taking
into consideration the obtained data, we can say the follow-
ing. The results of NMR spectra, discussed above, and the
results of the pharmacological activity, presented below, all
made in DMSO, give us reason to suggest that in these con-
ditions(inthesolutionofDMSO)thecomplexesarepresent.Irena Kostova et al. 5
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Figure 2: Experimental FT-Raman spectra of coumarin-3-carbox-
ylic acid (HCCA) and its Sm(III), Gd(III), and Dy(III) complexes
in the range 1800–200cm−1.
The stability of the complexes is of great interest with respect
to their further pharmacological properties (not cytotoxicity
test) and will be the subject of coming investigations which
are in progress.
Our previous molecular electrostatic potential (MEP)
study on the preferred reactive sites of CCA− in the gas phase
andinsolutionrevealedtworegionssuitableforelectrophilic
attackandbinding:betweenthedeprotonatedcarboxylicand
the carbonylic oxygens and between the carboxylic oxygens
[31, 32]. To suggest the binding mode of HCCA, a detail the-
oreticalandvibrationalinvestigationbasedonRaman,FTIR,
and DFT/B3LYP/SVP studies of HCCA, its deprotonated
form (CCA−), KCCA, and Ln(CCA)2(NO3)(H2O) species,
was performed. Two bidentate binding modes of CCA− to
Ln(III) were modeled: (1) through the deprotonated car-
boxylicandthecarbonylicoxygensand(2)throughbothcar-
boxylic oxygens. The vibrational analysis and the electronic
energycalculationspointedtotheﬁrstbindingasmoreprob-
able.OnthebasisofdetailedDFTstudyofthevibrationalbe-
havior of HCCA, CCA−, KCCA, and Ln(CCA)2(NO3)(H2O)
species and comparison of the theoretical and experimental
vibrational spectra, it was established that CCA− is biden-
tate bound to Ln(III) through the carboxylic and the car-
bonylic atoms. As seen from the vibrational spectra, the NO3
group is bidentate coordinated, the calculated and experi-
mental NO3 modes for the complexes were found at very
similar wavenumbers, and the assignment of the NO3 vi-
brational modes is in good agreement with literature data
[31, 32].
Moreover, the metal-ligand binding mode of coumarin-
3-carboxylic acid (HCCA) was recently explained by us
throughmodelingoftheLn(III)-coumarin-3-carboxylicacid
structures, where Ln = La,Ce,Nd [31, 32]. It was suggested
that coumarin-3-carboxylic acid binds to the Ln(III) ions
through both oxygen atoms of the carboxylic and carbonylic
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Figure 3: Cytotoxic eﬀect of Sm(CCA)2(NO3) ·H2Oo nt h e
chronic myeloid leukemia-derived K-562 cell line after 48-hour ex-
posure,asassessedbytheMTT-dyereductionassay.Eachdatapoint
represents the mean ± SD (n ≥ 6).
groups from the ligands and through the oxygen atoms of
NO3
−, and thus, the central ion Ln(III) is six-coordinated.
The NBO analysis of the complexes suggests predominantly
ionic character of the Ln−CCA bond with slight ligand-
metal charge transfer [31, 32].
Nevertheless, we have to take into consideration that the
coordination number 6 for these central metal ions indeed is
too low, but not impossible for lanthanide(III) ions [19–29,
31, 32]. One plausible mode of coordination might involve
also the water molecules, which is typical for coordination
compounds of lanthanides.
On the bases of our experimental spectral data and our
theoretical density function calculations [31, 32], we were
able to suggest the most probable structure of these Ln(III)
complexes.
3.3. Pharmacology
The preliminary pharmacological screening performed re-
vealedthatallofthelanthanidecomplexesexertedantiprolif-
erative eﬀects against the chronic myeloid leukemia-derived
K-562 line in a concentration-dependent matter, which en-
abled the construction of concentration response curves as
depicted on Figures 3, 4, 5, 6, 7, 8 and Table 3.I nc o n -
trast to the Sm(III) and Gd(III) complexes with coumarin-
3-carboxylic acid, Dy(CCA)2(NO3) ·H2O failed to induce
50% inhibition of the cellular proliferation within the con-
centration range under investigation.
Interestingly, the Gd(III) and Dy(III) nitrates were found
to exert considerable antiprolferative eﬀects (Figures 6, 7,
8), superior to those of the complexes thereof. In con-
trast, despite the considerable activity of the samarium
complex, the corresponding nitrate salt Sm(NO3)3 · 6H2O
(Figure 6) caused only marginal inhibitory eﬀects against K-
562 (Figure 3).6 Metal-Based Drugs
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Figure 4: Cytotoxic eﬀect of Gd(CCA)2(NO3) ·H2Oo nt h e
chronic myeloid leukemia-derived K-562 cell line after 48-hour ex-
posure,asassessedbytheMTT-dyereductionassay.Eachdatapoint
represents the mean ± SD (n ≥ 6).
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Figure5:CytotoxiceﬀectofDy(CCA)2(NO3) ·H2Oonthechronic
myeloid leukemia-derived K-562 cell line after 48-hour exposure,
as assessed by the MTT-dye reduction assay. Each data point repre-
sents the mean ± SD (n ≥ 6).
4. CONCLUSION
The results from this study demonstrate the antiprolfera-
tive potential of three novel lanthanide coordination com-
pounds of coumarin-3-carboxylic acid derivatives, in line
with our preceding papers concerning the activity of lan-
thanide (Ce(III), La(III), and Nd(III)) coordination com-
pounds with diverse coumarin ligands [19–29]. In our
hands,thesamarium(III)complexofcoumarin-3-carboxylic
acid proved to be the most active antiproliferative agent
among the novel complexes and thus it necessitates fur-
ther more detailed pharmacological evaluation. The com-
plex formation proved to be detrimental for the eﬃcacy of
Gd(III) and Dy(III) compounds as in both cases the nitrates
exerted superior eﬃcacy versus the corresponding coordina-
tion compounds.
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Figure 6: Cytotoxic eﬀect of Sm(NO3)3 ·6H2O on the chronic
myeloid leukemia-derived K-562 cell line after 48-hour exposure,
as assessed by the MTT-dye reduction assay. Each data point repre-
sents the mean ± SD (n ≥ 6).
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Figure 7: Cytotoxic eﬀect of Gd(NO3)3 ·6H2O on the chronic
myeloid leukemia-derived K-562 cell line after 48-hour exposure,
as assessed by the MTT-dye reduction assay. Each data point repre-
sents the mean ± SD (n ≥ 6).
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Figure 8: Cytotoxic eﬀect of Dy(NO3)3 ·5H2O on the chronic
myeloid leukemia-derived K-562 cell line after 48-hour exposure,
as assessed by the MTT-dye reduction assay. Each data point repre-
sents the mean ± SD (n ≥ 6).Irena Kostova et al. 7
Table 3: Relative potency of the investigated compounds in the
panel of human tumor cell line K-562, following 48-hour treatment
(MTT-dye reduction assay).
Compound IC50 value(a)
Sm(CCA)2(NO3) ·H2O 108.39 ±6.9μM
Gd(CCA)2(NO3) ·H2O 164.52 ±11.23μM
Dy(CCA)2(NO3) ·H2O >200μM
Sm(NO3)3 ·6H2O >200μM
Gd(NO3)3 ·6H2O4 1 .35 ±5.9μM
Dy(NO3)3 ·5H2O7 6 .78 ±4.72μM
(a)Data represent the arithmetic mean ± standard deviation of six
independent experiments.
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